The purpose of this study is to demonstrate faster time to extubation after arrival in the
cardiothoracic intensive care unit (ICU) in patients undergoing isolated coronary artery
bypass grafting (CABG), AVR and AVR/CABG combination who receive Sugammadex as compared to
placebo.